APA (7th ed.) Citation

Wang, D., Gao, J., Wang, J., Li, K., Wu, Z., Liao, Z., & Wu, Y. TFAP2A drives non-small cell lung cancer (NSCLC) progression and resistance to targeted therapy by facilitating the ESR2-mediated MAPK pathway. Nature Publishing Group.

Chicago Style (17th ed.) Citation

Wang, Ding-Guo, Jian Gao, Jing Wang, Kun-Chao Li, Zhi-Bo Wu, Zhong-Min Liao, and Yong-Bing Wu. TFAP2A Drives Non-small Cell Lung Cancer (NSCLC) Progression and Resistance to Targeted Therapy by Facilitating the ESR2-mediated MAPK Pathway. Nature Publishing Group.

MLA (9th ed.) Citation

Wang, Ding-Guo, et al. TFAP2A Drives Non-small Cell Lung Cancer (NSCLC) Progression and Resistance to Targeted Therapy by Facilitating the ESR2-mediated MAPK Pathway. Nature Publishing Group.